European equities traded in the US as American depositary receipts started the week off lower late Monday morning, declining 0.58% to 1,291.89 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma (ASND) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which increased 3.7% and 2.9%, respectively. They were followed by furniture maker Natuzzi (NTZ) and petroleum refined Equinor (EQNR), which were up 2.6% and 2.5%, respectively.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 6.1% and 5.8%, respectively. They were followed by 3D printer company Materialise (MTLS) and semiconductor company Sequans Communications (SQNS), which lost 4.2% and 3.2%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Trinity Biotech (TRIB), which climbed 11% and 4.4%, respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Akari Therapeutics (AKTX), which advanced 3.9% and 2.4%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Mereo BioPharma Group (MREO), which dropped 8.9% and 5.6%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which were down 4.9% and 4.7%, respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。